Home Products Antibodies Primary antibodies Secondary antibodies Tag antibodies Loading control antibodies Premium polyclonal antibodies Recombinant rabbit mAbs Mouse mAbs Phosphorylated antibodies Methylation antibodies Acetylated antibodies Biochemicals Research Areas
Service & Support Custom Services Support Promotion About Us
Sign In Sign Up

CNR1 Rabbit pAb  (Cat.#:AYP13970)

A
小A Scan to ask
Host: RabbitClonality: PolyclonalReactivity: Human,Mouse,RatWBIHC
Cat.# AYP13970
Target / gene CNR1
Host Rabbit
Clonality Polyclonal
Reactivity Human, Mouse, Rat
Application WB, IHC

Cat.#:AYP13970

SizePrice
50ul ¥1150.00 Add to cart
100ul ¥2100.00 Add to cart
  • Information

  • Application guide

  • Related products

  • Immunogen

  • Target data

  • Resources

  • Protocols

  • FAQs

Reactivity Human,Mouse,Rat
Host Rabbit
Clonality Polyclonal
Isotype IgG
Prediction WB: Homo sapiens
Application WBIHC
Dilution WB: 1:500 - 1:1000
IHC: 1:50 - 1:200
Predicted MW 45kDa/49kDa/52kDa
Observed MW 60KDa
Format Liquid
Storage Store at -20℃. Avoid freeze / thaw cycles.
Buffer: PBS with 0.05% proclin300,50% glycerol,pH7.3.
Conjugate Unconjugated
Positive Mouse liver,Mouse brain,Rat testis
Subcellular Cell membrane,Multi-pass membrane protein
Purification Affinity purification

Applications and conditions

Where to start

These starting conditions come from the recommended dilution, validation images, and general assay practice. Titrate for your sample and detection system.

WB Conditions for WB
Recommended dilution 1:500 - 1:1000
Suggested sample / positive control Mouse liver,Mouse brain,Rat testis
Key conditions Use a fresh lysate, incubate at the recommended dilution, and check the predicted and observed molecular weight
Expected result Expected signal or band near 60KDa
Controls Include a positive sample, a negative sample, and a secondary or isotype control
IHC Conditions for IHC
Recommended dilution 1:50 - 1:200
Suggested sample / positive control Mouse liver,Mouse brain,Rat testis
Key conditions For paraffin sections, optimize retrieval buffer pH, retrieval time, and primary incubation
Expected result Expected localization: Cell membrane,Multi-pass membrane protein
Controls Include a positive sample, a negative sample, and a secondary or isotype control

Related products

More associated products >>

Immunogen

Immunogen Recombinant fusion protein containing a sequence corresponding to amino acids 401-472 of human CNR1 (NP_001153698.1).
Sequence
View sequence
SKDLRHAFRSMFPSCEGTAQPLDNSMGDSDCLHKHANNAASVHRAAESCIKSTVKIAKVTMSVSTDTSAEAL

Target data

Background This gene encodes one of two cannabinoid receptors. The cannabinoids, principally delta-9-tetrahydrocannabinol and synthetic analogs, are psychoactive ingredients of marijuana. The cannabinoid receptors are members of the guanine-nucleotide-binding protein (G-protein) coupled receptor family, which inhibit adenylate cyclase activity in a dose-dependent, stereoselective and pertussis toxin-sensitive manner. The two receptors have been found to be involved in the cannabinoid-induced CNS effects (including alterations in mood and cognition) experienced by users of marijuana. Multiple transcript variants encoding two different protein isoforms have been described for this gene.
Gene ID 1268
Gene name CNR1
Swiss P21554
Synonym CNR1,CANN6,CB-R,CB1,CB1A,CB1K5,CB1R,CNR,CNR1 Rabbit pAb
Expression Widely expressed, with highest levels in fetal and adult brain. Expression levels of isoform 2 and isoform 3 are much lower than those of isoform 1.
Functions G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta9-tetrahydrocannabinol (THC) (PubMed:15620723, PubMed:27768894, PubMed:27851727). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP (PubMed:1718258, PubMed:21895628, PubMed:27768894). In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses. At high doses, CNR1 signal transduction involves G-protein alpha-i protein activation and subsequent inhibition of mitochondrial soluble adenylate cyclase, decrease in cyclic AMP concentration, inhibition of protein kinase A (PKA)-dependent phosphorylation of specific subunits of the mitochondrial electron transport system, including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive oxygen species (ROS) formation and mediates cannabinoid-induced increase in SREBF1 and FASN gene expression. In response to cannabinoids, drives the release of orexigenic beta-endorphin, but not that of melanocyte-stimulating hormone alpha/alpha-MSH, from hypothalamic POMC neurons, hence promoting food intake. In the hippocampus, regulates cellular respiration and energy production in response to cannabinoids. Involved in cannabinoid-dependent depolarization-induced suppression of inhibition (DSI), a process in which depolarization of CA1 postsynaptic pyramidal neurons mobilizes eCBs, which retrogradely activate presynaptic CB1 receptors, transiently decreasing GABAergic inhibitory neurotransmission. Also reduces excitatory synaptic transmission (By similarity). In superior cervical ganglions and cerebral vascular smooth muscle cells, inhibits voltage-gated Ca2+ channels in a constitutive, as well as agonist-dependent manner (PubMed:17895407). In cerebral vascular smooth muscle cells, cannabinoid-induced inhibition of voltage-gated Ca2+ channels leads to vasodilation and decreased vascular tone (By similarity). Induces leptin production in adipocytes and reduces LRP2-mediated leptin clearance in the kidney, hence participating in hyperleptinemia. In adipose tissue, CNR1 signaling leads to increased expression of SREBF1, ACACA and FASN genes (By similarity). In the liver, activation by endocannabinoids leads to increased de novo lipogenesis and reduced fatty acid catabolism, associated with increased expression of SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de novo cholesterol synthesis and HDL-cholesteryl ether uptake. Peripherally modulates energy metabolism (By similarity). In high carbohydrate diet-induced obesity, may decrease the expression of mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as well as that of selected glucose/ pyruvate metabolic enzymes, hence affecting energy expenditure through mitochondrial metabolism (By similarity). In response to cannabinoid anandamide, elicits a proinflammatory response in macrophages, which involves NLRP3 inflammasome activation and IL1B and IL18 secretion (By similarity). In macrophages infiltrating pancreatic islets, this process may participate in the progression of type-2 diabetes and associated loss of pancreatic beta-cells (PubMed:23955712).
Research area

Resources

Validation data

1 images

Validation images at the top of the page cover WB / IHC.

References

No papers are linked yet. Contact technical support for application examples.

Ask for examples
Customer reviews

No reviews yet. After use, you can submit a review and experiment images.

Send feedback
Support

Support can help confirm the application, sample, dilution, controls, and assay conditions.

Support center
Need help with the application?

Send the catalog number, application, sample type, and assay. Support can confirm dilution, controls, and COA or lot documents.

FAQs

Listed applications: WB, IHC. Use the validation images and recommended dilution as a starting point.
Send the catalog number and lot through the inquiry form. Support will help with the lot documents.
Use the recommended conditions as a starting concentration. Sample, fixation, and detection system may need a titration.

Protocols

Protocols
AYP13970